Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 08 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in price momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some bullish weekly technical indicators, the overall monthly outlook remains cautious, reflecting a complex interplay of market forces and investor sentiment within the Pharmaceuticals & Biotechnology sector.

GlaxoSmithKline Pharmaceuticals Ltd. reported a 15.69% year-on-year increase in net profit to ₹237.18 crores for Q1 FY27 ended June 2026, though sequential momentum faltered with a 14.64% quarter-on-quarter decline. The mid-cap pharmaceutical company, valued at ₹44,793 crores, delivered mixed signals as revenue growth of 16.55% YoY to ₹938.44 crores was overshadowed by margin compression and sequential profit deterioration.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent upgrade in daily price action, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the evolving technical landscape of this mid-cap pharmaceutical player, contextualising its price movements against broader market benchmarks and sectoral trends.

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s recent performance and underlying metrics suggest a complex outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a strong day change of 3.57%, the stock’s technical indicators reveal a transition from a mildly bearish trend to a sideways momentum, prompting a reassessment of its near-term outlook within the Pharmaceuticals & Biotechnology sector.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 17 July 2026, providing investors with an up-to-date view of the company’s performance and valuation.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 06 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical momentum, moving from a bearish to a mildly bearish stance as of late June 2026. Despite a modest day gain of 1.40%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes, contextualising them within the broader market and sector trends to provide investors with a comprehensive view of the stock’s current positioning.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

While the broader market showed resilience with the Sensex gaining nearly 1% on 12 Jun 2026, Glaxosmithkline Pharmaceuticals Ltd slipped to a fresh 52-week low of Rs. 2,095.95, marking a stark divergence from the general market trend.

For the second consecutive session, Glaxosmithkline Pharmaceuticals Ltd has slipped further, hitting a fresh 52-week low of Rs 2119 on 11 Jun 2026, marking a 3.03% decline over the last two days amid broader market volatility.

Glaxosmithkline Pharmaceuticals Ltd’s stock price declined to a fresh 52-week low of Rs.2136.05 on 8 June 2026, marking a significant downturn amid broader market weakness and company-specific factors. The stock has underperformed its sector and the broader market over the past year, reflecting a combination of valuation concerns and subdued growth metrics.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

For the fifth consecutive session, Glaxosmithkline Pharmaceuticals Ltd has closed lower, slipping to a fresh 52-week low of Rs 2,166.6 on 2 Jun 2026. This decline extends the stock’s year-long underperformance, with a 33.52% drop compared to the Sensex’s 9.04% fall over the same period.